Patent application number | Description | Published |
20120128679 | Human Antibodies to the Glucagon Receptor - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels. | 05-24-2012 |
20130251728 | Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia. | 09-26-2013 |
20130344538 | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels. | 12-26-2013 |
20140255419 | Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia. | 09-11-2014 |
20150337045 | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels. | 11-26-2015 |
Patent application number | Description | Published |
20120083597 | Enrichment of Low Molecular Weight DNA - The present invention provides, among other things, a simple, reproducible, and cost-effective method for enriching fetal or other low molecular weight nucleic acids in a biological sample. In certain embodiments, methods are provided for enriching fetal nucleic acids (e.g., fetal DNAs), typically comprising steps of adding a polymer such as PEG to a heterogeneous biological sample containing fetal DNA and high molecular weight non-fetal DNA such that the PEG precipitates substantially the high molecular weight non-fetal DNA, and purifying the fetal DNA from supernatant, thereby enriching the fetal DNA. | 04-05-2012 |
20120196285 | Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules - Methods for enriching specific microparticles, such as fetal microparticles or disease specific microparticles, in a biological sample are disclosed. In certain embodiments, the methods include combining a biological sample with a molecule that binds specific microparticles, and separating fractions of the biological sample, wherein the fraction that contains the binding molecule is enriched for the specific microparticles. Also disclosed are methods for enriching fetal nucleic acids by enriching fetal microparticles in a fraction of the biological sample and isolating nucleic acids from the enriched fraction. Methods for facilitating prenatal diagnosis of fetal chromosomal abnormalities are disclosed. In certain embodiments, the methods include combining a biological sample with a molecule that binds fetal microparticles, separating fractions of the biological sample, isolating nucleic acids from the fraction enriched for fetal microparticles, and analyzing the nucleic acids for the presence of a mutation. | 08-02-2012 |
20120264628 | Methods for Enriching Microparticles or Nucleic Acids in a Complex Mixture Using Size Exclusion Filtration - Embodiments of the present invention provide methods for the enrichment of rare microparticles, cells, or nucleic acids from a complex mixture using serial size exclusion filtration. Also provided are less invasive methods for detecting chromosomal or genetic abnormalities in a fetus, by enriching fetal microparticles in maternal plasma using serial size exclusion filtration, and isolating and analyzing the fetal nucleic acids from the fetal microparticles. Methods for diagnosis of diseases such as cancer are also provided, including enriching disease specific microparticles in the patient's plasma using serial size exclusion filtration, and isolating and analyzing the nucleic acids from the disease specific microparticles. | 10-18-2012 |
Patent application number | Description | Published |
20110191389 | DISTRIBUTED DATA MANAGEMENT SYSTEM - A distributed data management system has multiple virtual machine nodes operating on multiple computers that are in communication with each other over a computer network. Each virtual machine node includes at least one data store or “bucket” for receiving data. A digital hash map data structure is stored in a computer readable medium of at least one of the multiple computers to configure the multiple virtual machine nodes and buckets to provide concurrent, non-blocking access to data in the buckets, the digital hash map data structure including a mapping between the virtual machine nodes and the buckets. The distributed data management system employing dynamic scalability in which one or more buckets from a virtual machine node reaching a memory capacity threshold are transferred to another virtual machine node that is below its memory capacity threshold. | 08-04-2011 |
20110225205 | MULTI-QUERY OPTIMIZATION - A database query optimization method is provided for database queries that include predicates, the queries being directed to at least one database table having data in rows and columns. The method includes associating a lineage bit set with each row of the database table, the lineage bit set providing a binary predicate state indication whether each predicate is met or are not met by data in the row. A dependency bit set is established to provide a binary indication of the predicates that are included in each query. Queries are applied against the database table by a logical operation between the lineage bit set and the dependency bit set. A database query optimization data structure includes a lineage bit set associated with each row in the database table. The lineage bit set provides a binary predicate state indication whether each predicate is met or are not met by data in the row. The data structure further includes a dependency bit set that provides a binary indication of the predicates included in each query. | 09-15-2011 |
20140195566 | DISTRIBUTED DATA MANAGEMENT SYSTEM - A distributed data management system has multiple virtual machine nodes operating on multiple computers that are in communication with each other over a computer network. Each virtual machine node includes at least one data store or “bucket” for receiving data. A digital hash map data structure is stored in a computer readable medium of at least one of the multiple computers to configure the multiple virtual machine nodes and buckets to provide concurrent, non-blocking access to data in the buckets, the digital hash map data structure including a mapping between the virtual machine nodes and the buckets. The distributed data management system employing dynamic scalability in which one or more buckets from a virtual machine node reaching a memory capacity threshold are transferred to another virtual machine node that is below its memory capacity threshold. | 07-10-2014 |